MP14 - Infectious Diseases Group - IBS. GRANADA. XNUMXst Century

Information
Members
Publications
Projects
Clinical trials

Clinical research group focused on infectious pathology: HIV, HCV hepatitis, and osteoarticular infection.

OBJECTIVES: To assess the long-term adverse effects of currently used antiretroviral drugs; to investigate the efficacy and safety of new anti-HIV and anti-HCV drug targets; to investigate prognostic factors for virological response to these diseases. To determine the efficacy of antibiotics in cement spacers as a treatment for osteoarticular infection: to develop pharmacokinetic models of antibiotics in various prosthetic materials.

Research lines

Study of bacterial infections by multi-resistant microorganisms
Rational use of antibiotics - PROA
Study of new antimicrobials.
Study of endovascular infections (endocarditis)
New treatment strategies for people with HIV.
Study of anal, oropharyngeal and female genital dysplasia in people with HIV caused by HPV.
Vaccines

Keywords

HIV, HPV; ANAL CANCER, CERVICAL CANCER, ROPHARYNGEAL CANCER in people with HIV; dysplasia screening, HSIL, HSH, Endocarditis, Dalbavancin, Ceftobiprole, Cefi derocol, Dolutegravir, Bitherapy, Cabotegravir, rilpivirine, ART.

Maria del Mar Rivero Rodriguez

Maria Concepcion Lopez Robles

ORCID

SERGIO SEQUERA ARQUELLADAS

ORCID

Maria del Mar Arenas Miras

Miguel Angel Rodriguez Munoz

CAROLINA MERIDA FERNANDEZ

LEOPOLDO MUÑOZ MEDINA

ORCID

PETER BROWN MORENO

ORCID

JUAN PASQUAU LIANO

PABLO PEREZ VALLECILLOS

MARIA JOSE ROJAS VILCHEZ

DAVID VINUESA GARCIA

ORCID

JOSE FERNANDO FLORIDO LOPEZ

CORAL GARCIA VALLECILLOS

EMILIO GUIRAO ARRABAL

ORCID

CARMEN HIDALGO TENORIO

ORCID

ROSARIO JAVIER MARTINEZ

Mª ANGELES LARA JIMENEZ

MARIA CONCEPCION FERNANDEZ ROLDAN

ORCID

de Novales, FJM; de Pablo, OB; Estella, A; Ruiz, LM; Sempere, MRO; Lleti, MS; Muñoz, ME; Hidalgo-Tenorio, C

The Positioning of Ceftobiprole in Staphylococcus aureus Bacteremia

CLINICAL INFECTIOUS DISEASES, 2024;

FI: 8,2; D1

Gasca-Capote, C; Lian, XD; Gao, C; Roseto, IC; Jiménez-Léon, MR; Gladkov, G; Camacho-Sojo, MI; Perez-Gomez, A; Gallego, I; Lopez-Cortes, LE; Bachelor, S; Vitalle, J; Benhnia, MRE; Ostos, FJ; Collado-Romacho, AR; Santos, J; Palacios, R; Gomez-Ayerbe, C; Munoz-Medina, L; Ruiz-Sancho, A; Frias, M; Rivero-Juarez, A; Roca-Oporto, C; Hidalgo-Tenorio, C; Rull, A; Olalla, J; Lopez-Ruz, MA; Vidal, F; Vilades, C; Mastrangelo, A; Cavassini, M; Espinosa, N; Perreau, M; Peraire, J; Rivero, A; López-Cortes, LF; Lichterfeld, M; Yu, XG; Ruiz-Mateos, E

The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers

JOURNAL OF CLINICAL RESEARCH, 2024;

FI: 13,3; D1

Alvarez-Zaballos, S; Vázquez-Alen, P; Muñoz, P; de Alarcón, A; Carter, EG; Alvarez-Uría, A; Fariñas, MC; Rodríguez-García, R; Goenaga, M.A.; Raven, G; Plata-Ciezar, A; Hidalgo-Tenorio, C; Aldamiz-Echevarría, G; Martínez-Sellés, M

Prevalence and prognostic impact of stroke in a national cohort of infective endocarditis

INTERNATIONAL JOURNAL OF STROKE, 2024;

FI: 6,3; D1

Alonso-Menchén, D; Marín-Arriaza, M; Villamarín, M; Fernández-Hidalgo, N; López-Azor, JC; Calderón-Parra, J; Fernández-Paniagua, EA; Hidalgo-Tenorio, C; de Alarcón, A; Goenaga-Sanchez, MA; Rodríguez-Esteban, MA; Vázquez, EG; Grillo, S; Santiago, EB; Muñoz, P

Cutibacterium Species Valvular and Cardiac Device-Related Infective Endocarditis: Contemporary Data From the GAMES Prospective Cohort (2008-2023)

CLINICAL INFECTIOUS DISEASES, 2024;

FI: 8,2; D1

Corma-Gómez, A; Hair, A; Orviz, E; Morante-Ruiz, M; Ayerdi, O; Al-Hayani, A; Muñoz-Gómez, A; De Los Santos, I; Gómez-Ayerbe, C; Rodrigo, D; Riestra, SDR; Reus-Bañuls, S; Silva-Klug, A; Galindo, MJ; Santos, M; Serrano-Fuentes, M; Faro-Míguez, N; Pérez-Camacho, I; Corona-Mata, D; Morano, L; López-Ruz, MA; Montero, M; Anaya-Baz, B; Merino, D; Castillo-Navarro, A; Pineda, JA; Macías, J

Long or complicated mpox in patients with uncontrolled HIV infection

JOURNAL OF MEDICAL VIROLOGY, 2024;

FI: 6,8; D1

Hidalgo-Tenorio, C; Sadyrbaeva-Dolgova, S; Enríquez-Gómez, A; Muñoz, P; Plata-Ciezar, A; Miró, JM; Alarcón, A; Martínez-Marcos, FJ; Loeches, B; Escrihuela-Vidal, F; Vinuesa, D; Herrero, C; Boix-Palop, L; Arenas, MD; Vázquez, EG; de las Revillas, FA

EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023;

FI: 10,8; Q1

Garcia-Martinez, CM; Calle-Gomez, I; Lopez-Hidalgo, J; Gomez-Ronquillo, P; Balgahata, MOM; Hidalgo-Tenorio, C

Role of Low-Risk HPV PCR Monoinfection in Screening for HSIL and Anal Cancer in Men Who Have Sex with Men Living with HIV

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023;

FI: 6,208; Q1

Sadyrbaeva-Dolgova, S; Sanchez-Suarez, MD; Marquez, JAR; Hidalgo-Tenorio, C

The Challenge of Bacteremia Treatment due to Non-Fermenting Gram-Negative Bacteria

MICROORGANISMS, 2023;

FI: 4,5; Q2

Garcia-Ceberino, PM; Salazar-Gonzalez, A; Faro-Miguez, N; Fuentes-Lopez, A; Viñuela-Gonzalez, L; Palomares-Rodriguez, J; Valero-Ubierna, C; Ruiz-Villaverde, R; Garcia-Garcia, F; Hernandez-Quero, J; Ruiz-Sancho, A.L.

Monkeypox Virus Infection and Sexually Transmitted Infections: A Cross-Sectional Study from a Secondary Hospital in the May-September 2022 International Outbreak

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2023;

FI: 1,5; Q4

del Pino, MR; Rosales-Castillo, A; Hidalgo-Tenorio, C; Exposito-Ruiz, M; Navarro-Mari, JM; Gutierrez-Fernandez, J

Isolation of Haemophilus no ducreyi in samples from the genital tract of men: Its clinical relationship

International Journal of Andrology, 2023;

FI: 0,8; Q4

Gonzalez-Serna, A; Macias, J; Corma-Gomez, A; Tellez, F; Cucurull, J; Real, LM; Granados, R; Rivero-Juarez, A; Hernandez-Quero, J; Merino, D; Palacios, R; Rios, MJ; Collado, A; Pineda, J.A.

High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use

JOURNAL OF INFECTION, 2022;

FI: 38,637; D1

Bukkems, VE; Necsoi, C; Tenorio, CH; Garcia, C; Alejandre, IA; Weiss, F; Lambert, J.S. van Hulzen, A; Richel, O; te Brake, LHM; van der Meulen, E; Burger, D; Konopnicki, D; Colbers, A.

Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network

CLINICAL INFECTIOUS DISEASES, 2022;

FI: 20,999; D1

Rodriguez-Hernandez, MA; Rams, D; Nunez-Nunez, M; Coca, R; Baena, R; Lopez-Ruiz, GM; Cano-Serrano, ME; Martinez-Telleria, A; Fuentes-Lopez, A; Praena-Fernandez, JM; Garbers, C; Hernandez-Quero, J; Garcia, F; Rose-John, S; Bustos, M

Identification of IL-6 Signaling Components as Predictors of Severity and Outcome in COVID-19

FRONTIERS IN IMMUNOLOGY, 2022;

FI: 8,786; Q1

Gutierrez-Bautista, JF; Martinez-Chamorro, A; Rodriguez-Nicolas, A; Rosales-Castillo, A; Jimenez, P; Anderson, P; Lopez-Ruz, MA; Lopez-Nevot, MA; Ruiz-Cabello, F

Major Histocompatibility Complex Class I Chain-Related alpha (MICA) STR Polymorphisms in COVID-19 Patients

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022;

FI: 6,208; Q1

Gil-Rodriguez, J; Benavente-Fernandez, A; Guirao-Arrabal, E; Quero, JH

On lung ultrasound scoring for the early evaluation of patients with COVID-19 and dyspnea

EMERGENCIES, 2022;

FI: 5,345; Q1

Perez-Anton, E; Egui, A; Thomas, MC; Carrilero, B; Simon, M.; Lopez-Ruz, MA; Segovia, M.; Lopez, MC

A proportion of CD4(+) T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment

PLOS NEGLECTED TROPICAL DISEASES, 2021;

FI: 4,411; D1

Pericas, JM; Hernandez-Meneses, M; Munoz, P; Martinez-Selles, M; Alvarez-Uria, A; DeAlarcon, A; Gutierrez-Carretero, E; Goenaga, MA; Zarauza, MJ; Falces, C; Rodriguez-Esteban, MA; Hidalgo-Tenorio, C; Hernandez-Cabrera, M; I look, J.M.

Characteristics and Outcome of Acute Heart Failure in Infective Endocarditis: Focus on Cardiogenic Shock

CLINICAL INFECTIOUS DISEASES, 2021;

FI: 9,079; D1

Aomar-Millan, IF; Salvatierra, J.; Torres-Parejo, U; Faro-Miguez, N; Callejas-Rubio, JL; Ceballos-Torres, A; Cruces-Moreno, MT; Gomez-Jimenez, FJ; Hernandez-Quero, J; Anguita-Santos, F.

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.

INTERNAL AND EMERGENCY MEDICINE, 2021;

FI: 3,397; Q2

Aomar-Millan, IF; Salvatierra, J.; Hernandez-Quero, J.

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.-

INTERNAL AND EMERGENCY MEDICINE, 2021;

FI: 3,397; Q2

Suardi, L.R.; deAlarcón, A; Garcia, MV; Ciezar, A.P.; Tenorio, CH; Martinez-Marcos, FJ; Council-Martinez, E; Lima, J.D.; Garcia, DV; Marquez, R.L.; Ojeda, G.; Iglesias, JMR; Hills, JM; Lopez-Cortes, L.E.

Blood culture-negative infective endocarditis: a worse outcome? Results from a large multicentre retrospective Spanish cohort study

INFECTIOUS DISEASES, 2021;

FI: 3,404; Q3

Parejo-Moron, AI; Turner-Divieso, ML; Fernandez-Diaz, MR; Munoz-Medina, L; Preda, O; Ortego-Centeno, N

Necrotizing Sarcoid Granulomatosis: A Disease Not to be Forgotten

CASE REPORTS IN MEDICINE, 2020;

Gutierrez-Bautista, JF; Rodriguez-Nicolas, A; Rosales-Castillo, A; Jimenez, P; Garrido, F.; Anderson, P; Ruiz-Cabello, F; Lopez-Ruz, M.A.

Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset

FRONTIERS IN IMMUNOLOGY, 2020;

FI: 5,085; Q1

Zuniga, MAL; Chueca, N; de Salazar, A; Knight, JAF; Valencia, AG; Garcia, DV; Balgahata, MOM; Tenorio, CH; Lopez-Ruz, MA; Garcia, F

Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy.

SEXUALLY TRANSMITTED INFECTIONS, 2020;

FI: 3,396; Q2

Nunez-Nunez, M; Casas-Hidalgo, I; Garcia-Fumero, R; Vallejo-Rodriguez, I; Anguita-Santos, F; Hernandez-Quero, J; Head-Barrera, J; Ruiz-Sancho, A

Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labeled indications

EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2020;

FI: 0,892; Q4

Fernandez, NM; Sword, CL; Palomino, JPL; Vallecillos, PP; Rospide, VG

Migration and Surgical Retrieval of an Amplatzer Septal Occluder into Abdominal Aorta

ANNALS OF VASCULAR SURGERY, 2020;

FI: 1,125; Q4

Egui, A; Thomas, M.C.; Fernandez-Villegas, A; Perez-Anton, E; Gomez, I; Lane, B; del Pozo, A; Ceballos, M; Andres-Leon, E; Lopez-Ruz, MA; Gainza, E; Oquinena, E; Segovia, M; Lopez, M.C.

A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019;

FI: 4,715; D1

Garcia-Alvarez, L; Sanz, MM; Marin, M; Farinas, MC; Montejo, M; Goikoetxea, J; Garcia, RR; de Alarcon, A; Almela, M; Fernandez-Hidalgo, N; Socas, MMA; Goenaga, MA; Navas, E; Vicious, L; Oteo, JA; Adam, I; Sanchez, FF; Noureddine, M; Rosas, G; Lima, JD; Aramendi, J; Bereciartua, E; Boado, MV; Lazaro, MC; Goiti, JJ; Hernandez, JL; Iruretagoyena, JR; Zuazabal, JI; Lopez-Soria, L; Perez, PM; Rodriguez, R; Voices, R; Lopez, MVG; Georgieva, RI; Solero, MM; Bailon, IR; Morales, JR; Cuende, AM; Echeverria, T; Strong, A; Gaminde, E; Idigoras, P; Iribarren, JA; Yarza, AI; Urkola, XK; Reviejo, C; Carrasco, R; Climent, V; Llamas, P; Merino, E; Plazas, J; Reus, S; Alvarez, N; Bravo-Ferrer, JM; Castelo, L; Cuenca, J; Llinares, P; Rey, EM; May, MR; Sanchez, E; Regueiro, DS; Martinez, FJ; Alonso, MD; Castro, B; Marrero, DG; Duran, MD; Gomez, MAM; La Calzada, J; Nassar, I; Ciezar, AP; Iglesias, JMR; Alvarez, VA; Costas, C; de la Hera, J; Suarez, JF; Friar, LI; Arguero, VL; Menendez, JL; Low, PM; Morales, C; Torrico, AM; Palomo, C; Martinez, BP; Esteban, AR; Asensio, MT; Ambrosioni, J; Gunsmith, Y; Azqueta, M; Brunet, M; Cartana, R; Falces, C; Fita, G; Fuster, D; de la Maria, CG; Gatell, JM; Perez, JL; Manzardo, C; Marco, F; Miro, JM; Moreno, A; Ninot, S; Quintana, E; Stop, C; Pereda, D; Pericas, JM; Pomar, JL; Ramirez, J; Rovira, I; Sitges, M; I'm d; Tellez, A; Vidal, B; Vila, J; Bermejo, J; Bouza, E; Body, G; from Egea, V; Eworo, A; Cruz, AF; Leoni, MEG; del Vecchio, MG; Ramallo, VG; Hernandez, MK; Martinez-Selles, M; Menarguez, MC; Munoz, P; Rincon, C; Rodriguez-Abella, H; Rodriguez-Creixems, M; Pinilla, B; Pinto, A; Valerio, M; Moreno, EV; Antorrena, I; Loeches, B; Moreno, M; Ramirez, U; Baston, VR; Romero, M; Saldana, A; Castillo, CA; Arnaiz, A; Berrazueta, J; Bellisco, S; Belaustegui, MC; Duran, R; Farinas-Alvarez, C; Mazarrasa, CF; Left, RG; Rico, CG; Ten, JG; Duran, RM; Pajaron, M; Parra, JA; Teira, R; Zarauza, J; Pavia, PG; Gonzalez, J; Order, B; Ramos, A; Gonzalez, ER; Order, B; Ramos, A; Gonzalez, ER; Centella, T; Hermida, JM; Moya, JL; Martin-Davila, P; Olive, E; del Rio, A; Ruiz, S; Tenorio, CH; de Castro, A; de Cueto, M; Gallego, P; Acebal, JG; Bano, JR; Garcia, E; Haro, JL; Lepe, JA; Lopez, F; Luque, R; Alonso, LJ; Azcarate, P; Gutierrez, JMA; White, JR; de Benito, N; Gurgui, M; Pacho, C; Pericas, R; Pons, G; Alvarez, M; Fernandez, AL; Martinez, A; Prieto, A; Regueiro, B; Tijeira, E; Vega, M; Blasco, AC; Mollar, JC; Arana, JCG; Uriarte, OG; Lopez, AM; from Zarate, ZO; Matos, JAU; Nacle, MB; Sanchez-Porto, A; Vallejo, L; Leal, JMA; Vazquez, EG; Torres, AH; Blazquez, A; Valenzuela, GD; Alonso, A; Aramburu, J; Calvo, FE; Rodriguez, AM; Tarabini-Castellani, P; Galvez, EH; Bellido, CM; Pau, JL; Sepulveda, MA; Sierra, PT; Iqbal-Mirza, SZ; Alcolea, EC; Serrano, PE; Rock, JJH; Escobar, EM; Monk, AP; Cabrera, VS; Garcia, DV; Luna, CC; Morcillo, JN; Dry, MCP

Antimicrobial management of Tropheryma whipplei endocarditis: the Spanish Collaboration on Endocarditis (GAMES) experience

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019;

FI: 5,113; D1

Perez, AB; Chueca, N; Garcia-Deltoro, M; Martinez-Sapina, AM; Lara-Perez, MM; Garcia-Bujalance, S; Aldamiz-Echevarria, T; Vera-Mendez, FJ; Pineda, JA; Married, M; Pascasio, JM; Salmeron, J; Alados-Arboledas, JC; Poyato, A; Tellez, F; Rivero-Juarez, A; Merino, D; Vivancos-Gallego, MJ; Rosales-Zabal, JM; Garcia, F; Ocete, MD; Simon, MA; Rincon, P; Reus, S; Of the Church, A; Garcia-Arata, I; Jimenez, M; Jimenez, F; Hernandez-Quero, J; Galera, C; Balghata, MO; Primo, J; Masia, M; Espinosa, N; Delgado, M; von-Wichmann, MA; Collado, A; Santos, J; Minguez, C; Diaz-Flores, F; Fernandez, E; Bernal, E; De Juan, J; Anton, JJ; Velez, M; Aguilera, A; Navarro, D; Arenas, JI; Fernandez, C; Espinosa, MD; Rios, MJ; Alonso, R; Hidalgo, C; Hernandez, R; Tellez, MJ; Rodriguez, FJ; Antequera, P; Delgado, C; Martin, P; Crespo, J; Becerril, B; Perez, O; Garcia-Herola, A; Montero, J; Freyre, C; Grau, C

High efficacy of resistance-guided treatment of HCV patients failing NS5A inhibitors in the real world

Journal of Hepatology, 2019;

FI: 18,946; D1

Pericas, JM; Llopis, J; Gonzalez-Ramallo, V; Goenaga, MA; Munoz, P; Garcia-Leoni, ME; Farinas, MC; Pajaron, M; Ambrosioni, J; Luque, R; Goikoetxea, J; Oteo, JA; Carrizo, E; Bodro, M; Reguera-Iglesias, JM; Navas, E; Hidalgo-Tenorio, C; Miro, JM; Sanchez, FF; Noureddine, M; Rosas, G; Lima, JD; Blanco, R; Boado, MV; Lazaro, MC; Crespo, A; Goikoetxea, J; Iruretagoyena, JR; Zuazabal, JI; Lopez-Soria, L; Montejo, M; Nieto, J; Rodrigo, D; Rodriguez, R; Vitoria, Y; Voces, R; Lopez, MVG; Georgieva, RI; Ojeda, G; Bailon, IR; Morales, JR; Cuende, AM; Echeverria, T; Fuerte, A; Gaminde, E; Goenaga, MA; Idigoras, P; Iribarren, JA; Yarza, AI; Urkola, XK; Reviejo, C; Carrasco, R; Climent, V; Llamas, P; Merino, E; Plazas, J; Reus, S; Alvarez, N; Bravo-Ferrer, JM; Castelo, L; Cuenca, J; Llinares, P; Rey, EM; Mayo, MR; Sanchez, E; Regueiro, DS; Martinez, FJ; Alonso, MD; Castro, B; Rosado, DG; Duran, MD; Gomez, MAM; Lacalzada, J; Nassar, I; Ciezar, AP; Iglesias, JMR; Alvarez, VA; Costas, C; de la Hera, J; Suarez, JF; Fraile, LI; Arguero, VL; Menendez, JL; Bajo, PM; Morales, C; Torrico, AM; Palomo, C; Martinez, BP; Esteban, AR; Garcia, RR; Asensio, MT; Almela, M; Ambrosioni, J; Azqueta, M; Brunet, M; Bodro, M; Cartana, R; Falces, C; Fita, G; Fuster, D; de la Maria, CG; Garcia-Valls, L; Hernandez-Meneses, M; Perez, JL; Marco, F; Miro, JM; Moreno, A; Nicolas, D; Ninot, S; Quintana, E; Pare, C; Pereda, D; Pericas, JM; Pomar, JL; Ramirez, J; Rovira, I; Sandoval, E; Sala, M; Sitges, M; Soy, D; Tellez, A; Tolosana, JM; Vidal, B; Vila, J; Adan, I; Bermejo, J; Bouza, E; Celemin, D; Caballero, GC; Montero, AD; Cruz, AF; Mansilla, AG; Leoni, MEG; Ramallo, VG; Hernandez, MK; Hualde, AM; Marin, M; Martinez-Selles, M; Menarguez, MC; Munoz, P; Rincon, C; Rodriguez-Abella, H; Rodriguez-Creixems, M; Pinilla, B; Pinto, A; Valerio, M; Vazquez, P; Moreno, EV; Antorrena, I; Loeches, B; Quiros, AM; Moreno, M; Ramirez, U; Baston, VR; Romero, M; Saldana, A; Balbin, JA; Castillo, CA; Arnaiz, A; Revillas, FADL; Belaustegui, MC; Farinas, MC; Farinas-Alvarez, C; Izquierdo, RG; Garcia, I; Rico, CG; Gutierrez-Cuadra, M; Diez, JG; Pajaron, M; Parra, JA; Teira, R; Zarauza, J; Dominguez, F; Pavia, PG; Gonzalez, J; Orden, B; Ramos, A; Centella, T; Hermida, JM; Moya, JL; Martin-Davila, P; Navas, E; Oliva, E; del Rio, A; Stuart, JRR; Rodriguez, SR; Tenorio, CH; Delia, MA; Araji, O; Barquero, JM; Jambrina, RC; de Cueto, M; Acebal, JG; Mendez, I; Morales, I; Lopez-Cortes, LE; de Alarcon, A; Garcia, E; Haro, JL; Lepe, JA; Lopez, F; Luque, R; Alonso, LJ; Azcarate, P; Gutierrez, JMA; Blanco, JR; Garcia-Alvarez, L; Oteo, JA; Sanz, M; de Benito, N; Gurgui, M; Pacho, C; Pericas, R; Pons, G; Alvarez, M; Fernandez, AL; Martinez, A; Prieto, A; Regueiro, B; Tijeira, E; Vega, M; Blasco, AC; Mollar, JC; Arana, JCG; Uriarte, OG; Lopez, AM; de Zarate, ZO; Matos, JAU; Dominguez, GG; Sanchez-Porto, A; Leal, JMA; Vazquez, EG; Torres, AH; Blazquez, A; Valenzuela, GD; Alonso, A; Aramburu, J; Calvo, FE; Rodriguez, AM; Tarabini-Castellani, P; Galvez, EH; Bellido, CM; Pau, JL; Sepulveda, MA; Sierra, PT; Iqbal-Mirza, SZ; Alcolea, EC; Serrano, PE; Roca, JJH; Yanez, IK; Ballesta, AP; Soriano, V; Escobar, EM; Monje, AP; Cabrera, VS; Garcia, DV; Asenjo, MA; Luna, CC; Morcillo, JN; Seco, MCP; Gelabert, AV; Guallar, CA; Abad, NF; Mangas, PG; Adell, MM; Ruiz, MPP; Porres, JC; Vidal, BA; Trigueros, NC; Espin, MJD; Caro, JAG; Sanchez, RJ; Almazan, AJ; Freire, AO; Gonzalez, MV; Ramis, PP; Blanco, MAR; Bordes, ERD; Bonet, LV; Munera, MCB; Garaizabal, EE; Martinez, AT; Luque, JCS

Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort

CLINICAL INFECTIOUS DISEASES, 2019;

FI: 9,055; D1

Ruiz-Cabello, M.M.; Arrabal, EG; Medina, M.G.; Garcia, D.V.

An Atypical Radiological Presentation of Lung Adenocardnoma

ARCHIVES DE BRONCONEUMOLOGIA, 2019;

FI: 4,214; Q1

Perez-Valero, I; Pasquau, J; Rubio, R; Rivero, A; Santos, J; Sanz, J; Marino, A; Crespo, M; Hernandez-Quero, J; Iribarren, J.A.; Gutierrez, F; Terron, A; Stephen, H.; Perez-Molina, J.A.

Neurocognitive safety after 96 weeks on dual therapy with atazanavir / ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018;

FI: 5,217; D1

Pasquau, J; Hidalgo-Tenorio, C; Montes, ML; Romero-Palacios, A; Vergas, J; Sanjoaquin, I; Hernandez-Quero, J; Aguirrebengoa, K; Orihuela, F; Imaz, A; Rios-Villegas, MJ; Flores, J; Farinas, MC; Vazquez, P; Galindo, MJ; Garcia-Merce, I; Lozano, F; de los Santos, I; of Jesus, SE; Garcia-Vallecillos, C

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir / ritonavir monotherapy: A randomized clinical trial

PLOSONE, 2018;

FI: 2,766; Q1

Vicent, L; Saldivar, HG; Bouza, E; Munoz, P; Body, G; de Alarcon, A; Vidal, B; Cobo, M; Goenaga, MA; Carrasco-Chinchilla, F; Montejo, M; Galvez-Acebal, J; Hidalgo-Tenorio, C; Vinuesa-Garcia, D; Martinez-Selles, M

Prognostic implications of a negative echocardiography in patients with infective endocarditis

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018;

FI: 3,282; Q1

Dominguez-Molina, B; Ferrando-Martinez, S; Tarancon-Diez, L; Hernandez-Quero, J; Genebat, M; Vidal, F; Munoz-Fernandez, MA; Loyal, M; Koup, R; Ruiz-Mateos, E.

Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance - Supercontrollers

FRONTIERS IN IMMUNOLOGY, 2018;

FI: 5,511; Q1

Berenguer, J; Jarrin, I; Perez-Latorre, L; Hontanon, V; Vivancos, MJ; Navarro, J; Tellez, MJ; Guardiola, JM; Iribarren, JA; Rivero-Juarez, A; Marquez, M; Artero, A; Morano, L; Santos, I; Moreno, J; Farinas, MC; Galindo, MJ; Hernando, MA; Montero, M; Cifuentes, C; Domingo, P; Sanz, J; Domingez, L; Ferrero, OL; De la Fuente, B; Rodriguez, C; Reus, S; Hernandez-Quero, J; Gaspar, G; Perez-Martinez, L; Garcia, C; Force, L; Veloso, S; Losa, JE; Vilaro, J; Bernal, E; Arpone, S; Orti, AJ; Chocarro, A; Teira, R; Alonso, G; Silvarino, R; Vegas, A; Geijo, P; Bisbe, J; Esteban, H; Gonzalez-Garcia, J

Human Immunodeficiency Virus / Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant

OPEN FORUM INFECTIOUS DISEASES, 2018;

FI: 3,24; Q2

Gutierrez-Fernandez, J; Medina, V; Hidalgo-Tenorio, C; Abazi, R.

Two Cases of Neisseria meningitidis Proctitis in HIV-Positive Men Who Have Sex with Men

EMERGING INFECTIOUS DISEASES, 2017;

FI: 8,222; D1

Marques, J; Valle-Delgado, JJ; Urban, P; Baro, E; Prohens, R; Greater than; Cistero, P; Delves, M; Sinden, RE; Grandfils, C; de Paz, JL; Garcia-Salcedo, JA; Fernandez-Busquets, X

Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2017;

FI: 5,72; D1

Perez-Molina, JA; Rubio, R; Rivero, A; Pasquau, J; Suarez-Lozano, I; Riera, M; Estebanez, M; Palacios, R; Sanz-Moreno, J; Troy, J; Marino, A; Antela, A; Navarro, J; Esteban, H; Moreno, S

Simplification to dual therapy (atazanavir / ritonavir plus lamivudine) versus standard triple therapy [atazanavir / ritonavir plus two nucleos (t) ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017;

FI: 5,071; D1

Perez-Parra, S; Chueca, N; Alvarez, M; Pasquau, J; Omar, M; Collado, A; Vinuesa, D; Lozano, AB; Yebra, G; Garcia, F.

High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach

PLOSONE, 2017;

FI: 2,806; Q1

Sanchez-Maranon, M; Miralles, I; Aguirre-Garrido, JF; Anguita-Maeso, M; Millan, V; Ortega, R; Garcia-Salcedo, J.A.; Martinez-Abarca, F; Soriano, M.

Changes in the soil bacterial community along a pedogenic gradient

SCIENTIFIC REPORTS, 2017;

FI: 4,259; Q1

Torres-Cornejo, A; BenMarzouk-Hidalgo, OJ; Viciana, P; Sanchez, B; Lopez-Ruz, MA; Lopez-Cortes, LF; Gutierrez-Valencia, A.

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract.

CLINICAL MICROBIOLOGY AND INFECTION, 2016;

FI: 5,768; D1

Lopez-Cortes, LF; Castano, MA; Lopez-Ruz, MA; Rios-Villegas, MJ; Hernandez-Quero, J; Merino, D; Jimenez-Aguilar, P; Marquez-Solero, M; Terron-Pernia, A; Tellez-Perez, F; Viciana, P; Orihuela-Canadas, F; Palacios-Baena, Z; Vinuesa-Garcia, D; Fajardo-Pico, JM; Romero-Palacios, A; Ojeda-Burgos, G; Pascuau-Liano, J.

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens

PLOSONE, 2016;

FI: 3,234; Q1

Coronado-Alvarez, NM; Parra-Ruiz, J.

Vancomycin does not remain appropriate empiric therapy in coagulase-negative staphylococcal bacteremia.

JOURNAL OF INFECTION, 2016;

FI: 4,441; Q1

Garcia-Salcedo, J.A.; Unciti-Broceta, JD; Valverde-Pozo, J; Soriano, M.

New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites

FRONTIERS IN PHARMACOLOGY, 2016;

FI: 4,418; Q1

Lopez-Ruz, MA; Navas, P; Lopez-Zuniga, MA; Gonzalvo, M.C.; Sampedro, A; Pasquau, J; Hidalgo-Tenorio, C; Xavier, R; Castile, J.A.

Effect of Monotherapy with Darunavir / Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients

PLOSONE, 2016;

FI: 3,057; Q1

Garcia-Salcedo, J.A.; Unciti-Broceta, JD; Soriano, M.

Could specific cell targeting overcome resistance associated with current treatments for African trypanosomiasis?

NANOMEDICINE, 2015;

FI: 5,413; D1

Arias, JL; Unciti-Broceta, JD; Maceira, J; of the Castle, T; Hernandez-Quero, J; Magez, S; Soriano, M; Garcia-Salcedo, J.A.

Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis

JOURNAL OF CONTROLLED RELEASE, 2015;

FI: 7,705; D1

Unciti-Broceta, JD; Arias, JL; Maceira, J; Soriano, M; Ortiz-Gonzalez, M; Hemandez-Quero, J; Munoz-Torres, M; from Koning, HP; Magez, S; Garcia-Salcedo, JA

Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis

PLOS PATHOGENS, 2015;

FI: 7,562; D1

Villatoro, MJPDY; Unciti-Broceta, JD; Contreras-Montoya, R; Garcia-Salcedo, J.A.; Mezo, MAG; Unciti-Broceta, A; Diaz-Mochon, JJ

Amide-controlled, one-pot synthesis of tri-substituted slurries generates structural diversity and analogues with trypanocidal activity

SCIENTIFIC REPORTS, 2015;

FI: 5,578; D1

Perez-Molina, JA; Rubio, R; Rivero, A; Pasquau, J; Suarez-Lozano, I; Riera, M; Estebanez, M; Santos, J; Sanz-Moreno, J; Troy, J; Marino, A; Antela, A; Navarro, J; Esteban, H; Moreno, S

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos (t) ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomized, open-label, non-inferiority trial

LANCET INFECTIOUS DISEASES, 2015;

FI: 22,433; D1

Improving the diagnosis of hidden HIV infection and other sexually transmitted infections (STIs) by studying the contacts made by HIV-infected patients.

Funder: GILEAD SCIENCES EUROPE LTD

File number: GLD19_0113

Execution time: 23/03/2020 - 22/03/2022

PI: JUAN PASQUAU LIAÑO

PROOF OF CONCEPT CORIVER: IVERMECTIN AS ANTIVIRIC TREATMENT IN PATIENTS INFECTED BY SARS-COV2 (COVID19).

Funder: COUNCIL OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE AND UNIVERSITIES

File number: CV20-75519

Execution time: 05/09/2020 - 04/02/2021

PI: CARMEN HIDALGO TENORIO

15_0078 - GILEAD - CARMEN HIDALGO - Training course on: Antiretroviral treatment strategies in different scenarios of HIV patients, naïve, simplification, switch Long-term toxicity control

Funder: GILEAD SCIENCES INTERNATIONAL LTD.

File number: 15_0078

Execution time: 05/10/2015 - 04/10/2016

PI: CARMEN HIDALGO TENORIO

RESEARCH IN PREVENTION OF CONGENITAL CHAGAS DISEASE: Parasitological, placental and immunological markers - ELAC2014 / HID0328

Funder: CARLOS III HEALTH INSTITUTE - FEDER

File number: AC15 / 00037

Execution time: 01/01/2016 - 31/12/2018

PI: JUAN PASQUAU LIAÑO

Identification and validation of biomarkers to improve the control of congenital Chagas disease

Funder: CARLOS III HEALTH INSTITUTE - FEDER

File number: AC18 / 00010

Execution time: 01/01/2019 - 31/12/2021

PI: JUAN PASQUAU LIAÑO

Phase IV clinical trial on the safety and immunogenicity of Gardasil-9 vaccine in HIV-infected adult women

Funder: CARLOS III HEALTH INSTITUTE - FEDER

File number: PI19 / 00283

Execution time: 01/01/2020 - 31/12/2022

PI: CARMEN HIDALGO TENORIO

Association between clinical and microbiological efficacy and pharmacokinetic/pharmacodynamic parameters of dalbavancin for the treatment of infections caused by gram-positive microorganisms. (DAPHNE PROJECT)

Funder: SEVILLE HEALTH RESEARCH MANAGEMENT FOUNDATION

Test type: OBSERVATIONAL STUDY WITH MEDICINES

Execution time: 07/10/24 - 30/06/27

PI: CARMEN HIDALGO TENORIO

Efficacy and safety of continuous versus intermittent infusion of ampicillin and ceftriaxone for the treatment of infective endocarditis due to Enterococcus faecalis (DOßLEI study)

Funder: SEVILLE HEALTH RESEARCH MANAGEMENT FOUNDATION

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 09/09/2024 - 30/12/2028

PI: CARMEN HIDALGO TENORIO

Analysis of the suitability of the use of antibiotic prophylaxis in surgical procedures performed in Spain (ProA-Q)

Funder: SPANISH HOSPITAL PHARMACY FOUNDATION

Type of test: OBSERVATIONAL STUDY WITH MEDICATION

Execution time: 12/09/2023 - 28/02/2024

IP: SVETLANA SADYRBAEVA DOLGOVA

PseudoNOVA2 study. Design of optimized antimicrobial treatment guidelines for respiratory infections caused by Pseudomonas aeruginosa.

Funder: CONSORCI SANITARI MAR PARC DE SALUT DE BARCELONA

Type of test: OBSERVATIONAL STUDY WITH MEDICATION

Execution time: 22/11/2023 - 31/12/2025

PI: CARMEN HIDALGO TENORIO

Retrospective analysis of real-world use of cefiderocol for the treatment of Gram-negative infections as part of the early access program (PERSEUS study)

Funder: SHIONOGI SL

Type of test: OBSERVATIONAL STUDY WITH MEDICATION

Execution time: 09/02/2023 - 30/06/2023

PI: CARMEN HIDALGO TENORIO

Prospective observational study to evaluate the safety and effectiveness of two mixtures of modified allergenic extracts of Cupressus arizonica pollen with a mixture of 5 grass pollen or with Olea europaea pollen associated with microcrystalline tyrosine.

Financer: ALLERGY THERAPEUTICS IBERICA, SLU

Type of test: OBSERVATIONAL STUDY WITH MEDICATION

Execution time: 17/03/2023 - 31/12/2023

PI: JOSE FERNANDO FLORIDO LOPEZ

CABO-CHANCE: Real-life study on the use of long-acting cabotegravir/rilpivirine (CAB/RPV AP) in treatment-experienced patients living with HIV (PLHIV)

Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)

Type of test: OBSERVATIONAL STUDY WITH MEDICATION

Execution time: 26/07/2023 - 30/09/2026

PI: CARMEN HIDALGO TENORIO

Adaptive, randomized, double-blind (sponsor-open), placebo-controlled study to investigate the antiviral effect, safety, tolerability, and pharmacokinetics of VH3739937 in treatment-naïve HIV-1 positive adults

Funder: VIIV HEALTHCARE UK LIMITED

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 24/11/2023 - 30/10/2024

PI: CARMEN HIDALGO TENORIO

Multicenter, double-blind, randomized, placebo-controlled, parallel-group phase III clinical trial evaluating the clinical efficacy and safety of immunotherapy with the purified major allergen Cup a 1 in patients with allergic rhinoconjunctivitis.

Funder: DIATER DIAGNOSTIC AND THERAPEUTIC APPLICATIONS LABORATORY, SA

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 16/05/2023 - 30/11/2024

PI: JOSE FERNANDO FLORIDO LOPEZ

Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5245 for the treatment of COVID-19 in participants at high risk of disease progression

Funder: GILEAD SCIENCES, SLU

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 29/12/2022 - 05/12/2023

PI: CARMEN HIDALGO TENORIO

Retrospective, descriptive, multicenter study with chart review on cefiderocol in the treatment of patients with Acinetobacter spp infections. resistant to carbapenems. ARES

Funder: SHIONOGI BV

Test type: REST OF EEOO WITH MEDICATIONS

Execution time: 31/03/2022 - 30/04/2022

PI: CARMEN HIDALGO TENORIO

Retrospective Chart Review to Evaluate the Safety Profile of Ceftobiprole in Patients With Impaired Hepatic or Renal Function or Immunosuppression (RETRACE)

Financier: ADVANZ PHARMA SWITZERLAND SARL

Type of test: OBSERVATIONAL STUDY WITH MEDICATION

Execution time: 07/12/2022 - 31/12/2023

PI: CARMEN HIDALGO TENORIO

CEFTO-REALLIFE: real-life use of ceftobiprole in a Spanish multicenter hospital cohort.

Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)

Type of test: INDEPENDENT POST-AUTHORIZATION STUDY

Execution time: 09/06/2022 - 30/12/2022

PI: CARMEN HIDALGO TENORIO

Non-inferiority randomized clinical trial to evaluate the efficacy and safety of short treatment of uncomplicated enterococcal bacteremia

Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 11/03/2022 - 30/01/2025

Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia caused by Pseudomonas aeruginosa: a multicenter, randomized clinical trial (SHORTEN-2) with a DOOR/RADAR analysis

Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 24/01/2022 - 30/05/2025

IP: MIGUEL ANGEL LOPEZ ZUÑIGA

Efficacy and Safety of Intra-arterial Administration of REX-001 in the Treatment of Ischemic Ulcers in Patients With Rutherford Category 5 Potentially Dangerous Lower Extremity Chronic Ischemia and Diabetes Mellitus: A Pivotal, Adaptive, Placebo-Controlled Trial, double blind and with parallel groups.

Funder: IXAKA LIMITED

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 04/04/2022 - 30/12/2025

IP: PABLO PEREZ VALLECILLOS

Phase 2, multicenter, randomized, double-blind (within dose level), placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of TF0023 versus placebo in the treatment of COVID-19. XNUMX in hospitalized adults.

Funder: TECHFIELDS INC

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 10/08/2022 - 30/01/2024

PI: JUAN PASQUAU LIAÑO

Phase I/II, (first-in-human), multicenter, randomized, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of HBV vaccines based on GSK viral vectors Biologicals administered in a primary vaccination – booster schedule, with sequential or joint administration of an adjuvanted therapeutic protein vaccine (GSK3528869A) in patients with chronic hepatitis B (18-65 years), on treatment with nucleotide analogues (NA). (TH HBV VV-001)

Funder: GLAXOSMITHKLINE, SA

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 28/04/2022 - 30/12/2023

Multicenter, Randomized, Controlled Phase III Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Compared to Control in Adult Patients Requiring Hospitalization for Medical Treatment of Moderate COVID-19 Infection

Financier: PHARMA MAR, SA

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 11/01/2022 - 30/05/2022

PI: CARMEN HIDALGO TENORIO

ALLERGO DATA RECORD

Funder: SPANISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY

Type of test: INDEPENDENT POST-AUTHORIZATION STUDY

Execution time: 25/05/2021 - 30/05/2026

PI: JOSE FERNANDO FLORIDO LOPEZ

Retrospective Observational Study on Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections – DALBADIA Study

Financer: ANGELINI PHARMA ESPAÑA, SLU

Type of test: COMMERCIAL POST AUTHORIZATION STUDY

Execution time: 30/11/2021 - 30/06/2022

PI: JUAN PASQUAU LIAÑO

Real Life Study of Bictegravir, Emtricitabine and Tenofovir Alafenamide in HIV-1 infected treatment-naive patients using test and treat strategy. (BIC/NOW). FIB-BIC-2021-01.

Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)

Type of test: INDEPENDENT POST-AUTHORIZATION STUDY

Execution time: 06/07/2021 - 30/05/2023

PI: CARMEN HIDALGO TENORIO

Real Life Study of Bictegravir, Emtricitabine and Tenofovir Alafenamide in HIV-1 infected treatment-naive patients using test and treat strategy. (BIC/NOW). FIB-BIC-2021-01

Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)

Type of test: INDEPENDENT POST-AUTHORIZATION STUDY

Execution time: 06/07/2021 - 30/05/2023

PI: DAVID VINUESA GARCIA

Prospective observational study to evaluate the safety and effectiveness of immunotherapy with an olive and grass pollen allergoid in patients with seasonal allergic asthma. GOL study

Financer: ALLERGY THERAPEUTICS IBERICA, SLU

Type of test: COMMERCIAL POST AUTHORIZATION STUDY

Execution time: 06/08/2021 - 30/11/2022

PI: JOSE FERNANDO FLORIDO LOPEZ

CDC- Four-year effectiveness of covid-19 vaccines against severe disease and asymptomatic infection: the covidvac@spain study

Financing: FOUNDATION FOR BIOMEDICAL RESEARCH OF LA PAZ UNIVERSITY HOSPITAL

Type of test: INDEPENDENT POST-AUTHORIZATION STUDY

Execution time: 31/08/2021 - 31/08/2025

PI: CARMEN HIDALGO TENORIO

Pilot clinical trial to evaluate the efficacy, safety and tolerability of switching to treatment with Bictegravir/FTC/TAF (Biktarvy®) plus darunavir/cobicistat in heavily treated HIV-1 infected patients.

Financing: RIS ASSOCIATION (AIDS RESEARCH NETWORK)

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 21/01/2021 - 30/04/2022

PI: CARMEN HIDALGO TENORIO

A PHASE II/III, DOUBLE-BLIND, TWO-GROUP INTERVENTIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED TO PLACEBO IN SYMPTOMATIC NON-HOSPITALIZED ADULT PATIENTS WITH COVID-19 WHO HAVE

Funder: PFIZER, SLU

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 03/08/2021 - 30/03/2022

PI: JUAN PASQUAU LIAÑO

Phase III multicenter, randomized, controlled trial to determine the efficacy and safety of two dose levels of Plitidepsin compared to control in adult patients requiring hospitalization for medical treatment of

Financier: PHARMA MAR, SA

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 25/08/2021 - 30/09/2021

Clinical trial of efficacy and safety, prospective, multicenter, randomized, double-blind, placebo-controlled, with subcutaneous immunotherapy in patients with rhinitis/rhinocojunctivitis with or without mild to moderate asthma sensitized to grasses and/or

Financer: INMUNOTEK, SL

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 18/12/2020 - 30/09/2022

PI: JOSE FERNANDO FLORIDO LOPEZ

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSION

Funder: PFIZER, SLU

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 03/08/2021 - 30/09/2022

PI: JUAN PASQUAU LIAÑO

Phase II/III, randomized, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of 2 regimens of FP -07321332/Ritonavir administered orally to prevent symptoms of SARS -COV infection -

Funder: PFIZER, SLU

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 23/09/2021 - 30/12/2021

PI: JUAN PASQUAU LIAÑO

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ambrisenttan in patients with severe COVID-19.

Funder: NOORIK BIOPHARMACEUTICALS AG

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 26/02/2021 - 30/10/2021

PI: CARMEN HIDALGO TENORIO

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ambrisenttan in patients with severe COVID-19

Funder: NOORIK BIOPHARMACEUTICALS AG

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 26/02/2021 - 30/10/2021

CDC -Prevention of the development of sars-cov-2 (covid-19) disease by prophylactic administration of emtricitabine / tenofovir disoproxil and hydroxychloroquine in high-risk healthcare personnel: randomized, pl-controlled clinical trial

Funder: NATIONAL PLAN ON AIDS

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 06/04/2020 - 06/04/2021

PI: JUAN PASQUAU LIAÑO

CDC -Prevention of the development of sars-cov-2 (covid-19) disease by prophylactic administration of emtricitabine / tenofovir disoproxil and hydroxychloroquine in high-risk healthcare personnel: randomized clinical trial,

Funder: NATIONAL PLAN ON AIDS

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 07/04/2020 - 07/04/2021

PI: LEOPOLDO MUÑOZ MEDINA

Substitution of Dolutegravir for Raltegravir 1200 mg QD in HIV-infected patients who develop neuropsychiatric symptoms after initiating triple therapy. Pilot clinical study (Neuropsiquiatric Evolution After Introduction of Raltegravir QD in subs

Funder: ANDALUSIAN PUBLIC FOUNDATION FOR MALAGA RESEARCH IN BIOMEDICINE AND HEALTH

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 23/07/2020 - 30/06/2022

PI: CARMEN HIDALGO TENORIO

Dalbalencia in real clinical practice in Spain. a two-year retrospective study.

Funder: ANGELINI PHARMA ESPAÑA, SL

Type of test: COMMERCIAL POST AUTHORIZATION STUDY

Execution time: 07/04/2020 - 07/10/2020

PI: JUAN PASQUAU LIAÑO

Clinical and microbiological study on the impact of multidrug resistance on virulence and host response to Pseudomonas aeruginosa infection.

Funder: CONSORCI SANITARI MAR PARC DE SALUT DE BARCELONA

Type of test: INDEPENDENT POST-AUTHORIZATION STUDY

Execution time: 12/03/2020 - 30/12/2022

PI: CARMEN HIDALGO TENORIO

Efficacy of intravenous fosfomycin in complicated urinary tract infection with real-life conditions. Impact of MIC and baseline mutations. FOSFO-MIC project

Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE

Type of test: INDEPENDENT POST-AUTHORIZATION STUDY

Execution time: 31/01/2020 - 30/03/2021

PI: DAVID VINUESA GARCIA

Phase II study to evaluate the tolerability, safety and efficacy of sublingual immunotherapy in patients with allergy to grass pollen.

Funder: ROXALL MEDICINA ESPAÑA, SA

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 07/09/2020 - 30/11/2021

PI: JOSE FERNANDO FLORIDO LOPEZ

CDC-Phase I / II, multicenter, randomized and controlled clinical trial to assess the safety and efficacy of intravenous administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stem Cells in patients with pneumonia

Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 21/04/2020 - 21/04/2021

PI: CARMEN HIDALGO TENORIO

CDC-Phase II and III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of ABBV -47D11 in Out-of-Hospital COVID-19 Adults

Funder: ABBVIE SPAIN SLU

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 22/12/2020 -

PI: CARMEN HIDALGO TENORIO

A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients

Funder: VIR BIOTECHNOLOGY INC

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 30/10/2020 - 30/06/2021

PI: JUAN PASQUAU LIAÑO

Temocillin vs Meropenem for the Treatment of Third Generation Cephalosporin-Resistant Enterobacterial Bacteremia: A Randomized and Pragmatic Trial

Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 20/10/2020 - 30/10/2020

Sarilumab Clinical Trial in Hospitalized Adults With COVID-19 Presenting Cytokine Release Syndrome

Funder: UNIVERSITY FOUNDATION FOR THE DEVELOPMENT OF THE PROVINCE OF CORDOBA

Type of test: INDEPENDENT CLINICAL TRIAL

Execution time: 04/11/2020 -

PI: DAVID VINUESA GARCIA

Prospective, multicenter, randomized, open, uncontrolled clinical trial in relation (1: 1), of parallel groups, with subcutaneous immunotherapy in mixed polymerized presentation (100: 100), in patients with rhinoconjunctivitis sensitized to the following combination of pollen: Phleum Pratense and Olea Europaea and administered according to different guidelines

Funder: ROXALL MEDICINA ESPAÑA, SA

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 29/07/2015 - 30/06/2016

PI: Mª ANGELES LARA JIMENEZ

Phase 2a, randomized, double-blind, placebo-controlled pilot study to investigate antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of two doses of JNJ-53718678 in non-hospitalized adult patients infected with respiratory syncytial virus

Funder: JANSSEN SCIENCES IRELAND UC

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 10/01/2018 - 30/08/2020

PI: JUAN PASQUAU LIAÑO

Phase 2, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and antiviral activity of JNJ-63623872 in combination with oseltamivir in adult and elderly adolescent patients hospitalized for influenza A infection.

Funder: JANSSEN-CILAG INTERNATIONAL NV

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 02/11/2015 - 30/04/2017

Phase 2, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and antiviral activity of JNJ-63623872 in combination with oseltamivir in adolescent, adult and elderly patients hospitalized for influenza A infection.

Funder: JANSSEN-CILAG INTERNATIONAL NV

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 07/11/2016 - 30/04/2018

PI: JUAN PASQUAU LIAÑO

Phase 2b, randomized, double-blind, placebo-controlled study to evaluate antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of orally administered study drug regimens in hospitalized adult patients with respiratory syncytia virus infection.

Funder: JANSSEN-CILAG INTERNATIONAL NV

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 03/11/2016 - 31/12/2018

PI: JUAN PASQUAU LIAÑO

Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of SCY-078 Combination Therapy with Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)

Funder: SYNEOS HEALTH IVH UK LIMITED (FORMERLY INVENTIV HEALTH CLINICAL UK LTD),

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 23/09/2019 - 30/04/2020

PI: JUAN PASQUAU LIAÑO

Phase IIb, comparative, multicenter, randomized, double-blind study to evaluate the efficacy and safety of intravenous VIS410 administered together with oseltamivir (tamiflu) compared with oseltamivir as monotherapy in hospitalized adults with influenza A virus infection. that require oxygen support

Funder: VISTERRA INC

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 21/12/2017 - 30/10/2019

MP14-Infectious Diseases Group-ibs.Granada. XNUMXst Century

Research lines

Keywords

Maria del Mar Rivero Rodriguez

Maria Concepcion Lopez Robles

SERGIO SEQUERA ARQUELLADAS

Maria del Mar Arenas Miras

Miguel Angel Rodriguez Munoz

CONCEPTION GARCIA GARCIA

MIGUEL ANGEL LOPEZ ZUNIGA

SVETLANA SADYRBAEVA DOLGOVA

CRISTINA LOPEZ ESPADA

CAROLINA MERIDA FERNANDEZ

LEOPOLDO MUÑOZ MEDINA

PETER BROWN MORENO

JUAN PASQUAU LIANO

PABLO PEREZ VALLECILLOS

MARIA JOSE ROJAS VILCHEZ

DAVID VINUESA GARCIA

JOSE FERNANDO FLORIDO LOPEZ

CORAL GARCIA VALLECILLOS

EMILIO GUIRAO ARRABAL

CARMEN HIDALGO TENORIO

ROSARIO JAVIER MARTINEZ

Mª ANGELES LARA JIMENEZ

MARIA CONCEPCION FERNANDEZ ROLDAN

Research